• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>IIC:International review of intellectual property and competition law >Assessing Access to Medicines in Preferential Trade Agreements: From the Trans-Pacific Partnership to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership
【24h】

Assessing Access to Medicines in Preferential Trade Agreements: From the Trans-Pacific Partnership to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership

机译：评估优惠贸易协定中的药品获取情况：从跨太平洋伙伴关系到跨太平洋伙伴关系的全面和渐进协议

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP or TPP11) is a trade agreement between Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam. CPTPP negotiations started after the Trans-Pacific Partnership Agreement reached a stalemate due to the withdrawal of the United States on 23 January 2017. This paper’s aim is to provide an appraisal of some sensitive provisions of the CPTPP, and their impact on access to affordable medicines. As access to medicines is mainly related to the protection of intellectual property rights and in particular patents, a first part of the paper will focus on the international regulatory framework for patents, considering the main international conventions, the TRIPS Agreement and its relation with preferential trade agreements. The narration will then focus on the provision of the CPTPP relating to patents and pharmaceuticals, and those relating to investment. The discussion will revolve around whether said provisions significantly depart from the framework set by TRIPS, for instance, including TRIPS-plus provisions, notably criticised for their adverse repercussions on the fundamental right to health. As regards the provisions in the investment chapter, the analysis will focus on whether the wording of said chapter is equipped to strike a balance between protection of foreign investors and health regulation. A conclusion will follow, summarising the main findings of the paper.
机译：《跨太平洋伙伴关系全面进步协议》（CPTPP或TPP11）是澳大利亚，文莱达鲁萨兰国，加拿大，智利，日本，马来西亚，墨西哥，新西兰，秘鲁，新加坡和越南之间的贸易协议。由于美国于2017年1月23日退出《跨太平洋伙伴关系协定》而陷入僵局，因此开始了CPTPP谈判。本文的目的是评估CPTPP的一些敏感条款及其对获得可负担药品的影响。由于药品的获取主要与知识产权特别是专利的保护有关，因此本文的第一部分将着眼于专利的国际监管框架，同时考虑主要的国际公约，TRIPS协议及其与优惠贸易的关系。协议。然后，叙述将集中于有关专利和药品以及与投资有关的CPTPP的规定。讨论将围绕上述条款是否与TRIPS设定的框架大相径庭，例如，包括TRIPS-plus条款，因其对基本健康权的不利影响而受到特别批评。关于投资一章的规定，分析将集中在该章的措词是否有能力在保护外国投资者和卫生法规之间取得平衡。得出结论，总结了论文的主要发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号